Carcinoma of the prostate. Hormonal therapy.
A selective review of the literature regarding hormonal therapy for patients with carcinoma of the prostate is presented to assess the current status of the following: therapeutic advantages, disadvantages and risks of alternate approaches to hormonal therapy; observations to predict the magnitude and duration of response to therapy; indications for initiating hormone therapy; the short-term and long-term effects of therapy; and role of hormone therapy in patients with recurrent tumor activity after initial hormonal measures.
Grayhack
J T
JT
Keeler
T C
TC
Kozlowski
J M
JM
D000315:Adrenalectomy; D000726:Androgen Antagonists / Q000627:therapeutic use; D000728:Androgens / Q000378:metabolism*; D004967:Estrogens / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D007016:Hypophysectomy; D008297:Male; D009364:Neoplasm Recurrence, Local; D009919:Orchiectomy / Q000009:adverse effects; D011372:Progestins / Q000627:therapeutic use; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000628:therapy*
D000726:Androgen Antagonists; D000728:Androgens; D004967:Estrogens; D011372:Progestins; D007987:Gonadotropin-Releasing Hormone